参考文献

1) Jurisic V, et al. Clinical stage-depending decrease of NK cell activity in multiple myeloma patients.Med Oncol.2007;24(3):312-317.

2) Cheng M, et al. NK cell-based immunotherapy for malignant diseases.Cell Mol Immunol.2013;10(3):230-252.

3) Marcus A, et al. Recognition of tumors by the innate immune system and natural killer cells.AdvImmunol.2014;122:91-128.

4) Bae J, et al. Dendritic cells and peptide-based vaccine in multiple myeloma. In: Munshi NC, Anderson KC, eds.Advances in Biology and Therapy of Multiple Myeloma: Volume 2:Translational and Clinical Research.New York, NY: Springer Science+Business Media; 2013:131-154.

5) Campbell KS, Purdy AK. Structure/function of human killer cell immunoglobulin-like receptors: lessons from polymorphisms, evolution, crystal structures and mutations. Immunology.2011;132(3):315-325.

6) Carbone E, et al. HLA class I, NKG2D, and natural cytotoxicity receptors regulate multiple myeloma cell recognition by natural killer cells. Blood.2005;105(1):251-258.

7) Murillo O, et al. Therapeutic antitumor efficacy of anti-CD137 agonistic monoclonal antibody in mouse models of myeloma. Clin Cancer Res. 2008;14(21):6895-6906.

8) Gullo C, et al. Inhibition of proliferation and induction of apoptosis in multiple myeloma cell lines by CD137 ligand signaling. PLoS One. 2010;26(5):e10845.

9) Spruance SL, Reid JE, Grace M, Samore M. Hazard ratio in clinical trials. Antimicrob Agents Chemother. 2004;48(8):2787-2792.

10) Brody T. Biostatistics. In: Clinical Trials: Study Design, Endpoints and Biomarkers, Drug Safety, and FDA and ICH Guidelines.London: Elsevier; 2012:165-190.

11) Blagoev KB, Wilkerson J, Fojo T. Hazard ratios in cancer clinical trials—a primer. Nat Rev Clin Oncol.2012;9(3):178-183.

このサイトは、患者の皆様やご家族の方などを対象にブリストル・マイヤーズ スクイブ株式会社の医療用医薬品を正しくご理解いただくために作成したものです。